UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 18, 2007
AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50761 11-3146460
(State or Other Jurisdiction (Commission File (IRS Employer
of Incorporation) Number) Identification No.)
603 Queensbury Avenue, Queensbury, New York 12804
(Address of Principal Executive Offices) (Zip Code)
(518) 798-1215
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2 (b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4 (c))
Item 2.02 Results of Operations and Financial Condition
On July 24, 2007, AngioDynamics, Inc. (the "Company") issued a press
release, a copy of which is attached as Exhibit 99.1, announcing its financial
results for the fourth quarter and fiscal year ended June 2, 2007 and that it
will hold a conference call beginning at 4:30 p.m. Eastern time, which will also
be webcast live, to discuss the announcement.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal
Year
On July 18, 2007, pursuant to the Company's amended and restated
bylaws, the Board of Directors of the Company unanimously approved a change in
the Company's fiscal year beginning in fiscal year 2008 to establish fiscal
quarters that will end on August 31, November 30, February 28 (or 29 as the case
may be), and May 31. Results for the fiscal year ended June 2, 2007 will be
filed with the Securities and Exchange Commission on Form 10-K on or prior to
August 16, 2007 and results for the period from June 3, 2007 to August 31, 2007
will be filed with the Securities and Exchange Commission on Form 10-Q on or
prior to October 10, 2007.
Forward-Looking Statements
This document and its attachments include "forward-looking statements"
intended to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Investors can identify these
statements by the fact that they do not relate strictly to historical or current
facts. These statements contain words such as "may," "will," "predict,"
"project," "might," "expect," "believe," "anticipate," "plan," "intend,"
"potential," "could," "would," "should," "estimate," "seek," "continue,"
"pursue," or "our future success depends," or the negative or other variations
thereof or comparable terminology. In particular, they include statements
relating to, among other things, future actions, strategies, future performance,
future financial results of the Company. These forward-looking statements are
based on current expectations and projections about future events.
Investors are cautioned that forward-looking statements are not
guarantees of future performance or results and involve risks and uncertainties
that cannot be predicted or quantified and, consequently, the actual performance
or results of the Company may differ materially from those expressed or implied
by such forward-looking statements. Such risks and uncertainties include, but
are not limited to, the factors described from time to time in the Company's
reports filed with the SEC, including the Company's Form 10-K for the fiscal
year ended June 3, 2006 and Form 10-Q for the period ended March 3, 2007,
financial community and rating agency perceptions of the Company; the effects of
economic, credit and capital market conditions on the economy in general, and on
medical device companies in particular; domestic and foreign health care reforms
and governmental laws and regulations; third-party relations and approvals,
technological advances and patents attained by competitors; and challenges
inherent in new product development, including obtaining regulatory approvals.
In addition to the matters described above, the ability of the Company to
develop its products, future actions by the FDA or other regulatory agencies,
results of pending or future clinical trials, the outcome of pending patent
litigation, overall economic conditions, general market conditions, market
acceptance, foreign currency exchange rate fluctuations, and the effects on
pricing from group purchasing organizations and competition, may affect the
actual results achieved by the Company.
Any forward-looking statements are made pursuant to the Private
Securities Litigation Reform Act of 1995 and, as such, speak only as of the date
made. The Company disclaims any obligation to update the forward-looking
statements. Investors are cautioned not to place undue reliance on these
forward-looking statements which speak only as of the date stated, or if no date
is stated, as of the date of this document.
Item 9.01 - Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press Release dated July 24, 2007.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ANGIODYNAMICS, INC.
(Registrant)
Date: July 25, 2007 By: /s/ Joseph Gersuk
---------------------------------
Joseph Gersuk
Chief Financial Officer
5
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press Release dated July 24, 2007.